Ursodeoxycholic Acid Market : Company Details, Development Trends and Competitors Analysis of International Market with Growth 2026Ursodeoxycholic Acid Market : Company Details, Development Trends and Competitors Analysis of International Market with Growth 2026
Ursodeoxycholic acid (UDCA) is a bile acid taken
as either a tablet or liquid to treat gallstones and to treat and
prevent the progression of cystic fibrosis-related liver disorder.
UDCA modifies the bile acid pool by decreasing levels of hydrophobic
bile acids while increasing proportion of nontoxic hydrophilic bile
acids. UDCA can delay development of gastroesophageal varices and
progression to cirrhosis. Moreover it can improve long-term survival
in patients with primary biliary cirrhosis.
Significant improvement in liver health can be
achieved during UDCA therapy in patients with intrahepatic
cholestasis of pregnancy, primary sclerosing cholangitis,
nonalcoholic fatty liver disease, cystic fibrosis-associated liver
disease, total parenteral nutrition-induced cholestasis, graft
related liver disease, and in some pediatric cholestatic liver
diseases.
The global ursodeoxycholic acid market size was
valued at US$ 346.2 million in 2017, and is expected
to witness a CAGR of 7.0% over the forecast period
(2018 – 2026).
Increasing prevalence of gall stones and
cystic fibrosis is expected to drive growth of the ursodeoxycholic
acid market
Ursodeoxycholic acid is increasingly being used
for the treatment of chronic cholestatic liver diseases. Increasing
prevalence of cystic fibrosis and gall stones is a major factor
driving growth of the global ursodeoxycholic acid market during the
forecast period. According to the Cystic Fibrosis Foundation 2015
data, around 30,000 people suffered from cystic fibrosis in the U.S.
Moreover, around 1,000 new cases of cystic fibrosis are diagnosed in
the country, annually. According to the American Gastroenterological
Association 2017 report, gallstones is affecting 10-15% of the U.S.
population annually, which accounts for around 25 million people.
Women are more likely to develop gallstones in
comparison to men. High estrogen levels during pregnancy, birth
control pills or hormone replacement therapy are the major factors
that produce gallstones in women. Moreover, occurrence of gallstones
is also high in older adults and individuals with a family history of
gallstones. Surgery is the usual treatment for symptomatic
gallstones, however treatment with ursodeoxycholic acid can dissolve
smaller stones, which are made mainly of cholesterol.
Detailed Segmentation:
-
Global Ursodeoxycholic Acid Market, By Dosage Form:
-
Liquid
-
Solid
-
-
Global Ursodeoxycholic Acid Market, By Mode of Extraction:
-
Synthetic
-
Biological
-
-
Global Ursodeoxycholic Acid Market, By Application:
-
Gallstones
-
Cystic Fibrosis
-
Liver Cirrhosis
-
Others
-
-
Global Ursodeoxycholic Acid Market, By Region:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East
-
Africa
-
-
Ursodeoxycholic Acid Market - Competitive
Landscape
Key players operating in the global
ursodeoxycholic acid market include, Abil Chempharma, Arcelor
Chemicals, Biotavia Labs, Daewoong Chemical, Dipharma Francis,
Erregierre, Grindeks, ICE, Mitsubishi Tanabe, Pharma Zell, Suzhou
Tianlu, and Zhangshanbelling.
Request For Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/2199
About Coherent
Market Insights
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market
Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702

Comments
Post a Comment